|
CCDC21 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.31110000423496E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.25609999956922E-07 |
| Normal-vs-Stage2 |
1.157310E-03 |
| Normal-vs-Stage3 |
5.52890000449224E-09 |
| Normal-vs-Stage4 |
4.59760000071086E-08 |
| Stage1-vs-Stage2 |
3.615400E-01 |
| Stage1-vs-Stage3 |
1.980610E-01 |
| Stage1-vs-Stage4 |
2.971800E-01 |
| Stage2-vs-Stage3 |
8.821500E-02 |
| Stage2-vs-Stage4 |
1.132820E-01 |
| Stage3-vs-Stage4 |
9.560200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.13420001063491E-09 |
| Normal-vs-AfricanAmerican |
1.308320E-02 |
| Normal-vs-Asian |
1.8927599999996E-05 |
| Caucasian-vs-AfricanAmerican |
1.340810E-01 |
| Caucasian-vs-Asian |
5.188600E-01 |
| AfricanAmerican-vs-Asian |
3.423800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.36630000038929E-07 |
| Normal-vs-Female |
8.38519997881093E-09 |
| Male-vs-Female |
8.691400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.81879999739243E-09 |
| Normal-vs-Age(41-60Yrs) |
1.10790000507066E-08 |
| Normal-vs-Age(61-80Yrs) |
1.64840999999916E-05 |
| Normal-vs-Age(81-100Yrs) |
6.320800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.024600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.786800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.370600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.335800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.902600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.508000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.74310000003553E-06 |
| Classical-VS-Follicular |
5.391700E-02 |
| Classical-VS-Other |
2.200400E-01 |
| Classical-VS-Normal |
1.19940000153917E-08 |
| Tall-VS-Follicular |
5.66400000012734E-07 |
| Tall-VS-Other |
6.823200E-01 |
| Tall-VS-Normal |
4.27435864480685E-14 |
| Follicular-VS-Other |
1.256220E-02 |
| Follicular-VS-Normal |
1.799390E-03 |
| Other-VS-Normal |
3.201500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.10169999976296E-08 |
| Normal-vs-N1 |
1.74670000685495E-09 |
| N0-vs-N1 |
5.632500E-02 |
|
|
